AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01896349
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
Trial: NCT02332512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01550549
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
Trial: NCT03063866
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 0.5 ug/kg
Trial: NCT01704196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01298934
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
Trial: NCT01449162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01608347
Drug: LMWH+Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
Trial: NCT01608347
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
Trial: NCT01289561
Drug: Alcohol + Caffeine Beverage
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Trial: NCT01289561
Drug: Alcohol + Caffeine-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Trial: NCT01284920
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02484040
Drug: Two-week course of radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capecitabine, 825mg/m2, bid
Trial: NCT03086369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01339689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, bid, up to 12 weeks
Trial: NCT01370902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
Trial: NCT01370902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
Trial: NCT01370902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered intravenously (into a vein), as a comparator at all dose levels
Trial: NCT00014040
Drug: Nitric Oxide and INOpulse Delivery System
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04127721
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02430389
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
Trial: NCT02430389
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
Trial: NCT00572377
Drug: FemLife Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Trial: NCT00572377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
Trial: NCT02192190
Drug: LY2951742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT02192190
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00281528
Drug: ABI-007 (Abraxane)
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute infusions
Trial: NCT00605852
Drug: GSK835726
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK835726 will be available in single dose and repeat dose formulations.
Trial: NCT00605852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to subjects.
Trial: NCT02582736
Drug: typical antipsychotics
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
Trial: NCT00233090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dose of placebo for four weeks.
Trial: NCT03688269
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 2ml Saline 0.9%
Trial: NCT00003468
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT02239562
Drug: sPIF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02239562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00655265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01893996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02341560
Drug: QPI-1007 Injection - 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02341560
Drug: QPI-1007 Injection - 3.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01402089
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
Trial: NCT02064673
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally twice a day
Trial: NCT00484055
Drug: Local application of collagen-gentamicin
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
Trial: NCT02289118
Drug: [18F]-T807 imaging tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau Imaging tracer
Trial: NCT06071533
Drug: Dandshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dandshen injection 20ml /day
Trial: NCT00328822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02358863
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
Trial: NCT00610649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered matching placebo capsules.
Trial: NCT01149707
Drug: PUR 0110 Rectal Enema 250 mg
RxNorm normalized name: Pur-Oxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
Trial: NCT01149707
Drug: PUR 0110 Rectal Enema 500 mg
RxNorm normalized name: Pur-Oxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
Trial: NCT01149707
Drug: PUR 0110 Rectal Enema 1000 mg
RxNorm normalized name: Pur-Oxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
Trial: NCT01149707
Drug: Placebo Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Enema, once-daily, intrarectally
Trial: NCT04252586
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
Trial: NCT00232180
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone administered on top of background standard heart failure therapy
Trial: NCT01295697
Drug: EZN-2208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT02748317
Drug: Lactobacillus rhamnosus GG
RxNorm normalized name: Lactobacillus rhamnosus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
Trial: NCT02358863
Drug: Docetaxel/Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
Trial: NCT02358863
Drug: IRI/EPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
Trial: NCT01696396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to abrilumab administered by subcutaneous injection
Trial: NCT01925469
Drug: Benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01925469
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A saline spray will be used in the placebo group
Trial: NCT01718041
Drug: Experimental: VRS-317
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment arm
Trial: NCT00485459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04556539
Drug: SC10914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg TID, oral admination on fasting condition
Trial: NCT00278967
Drug: HalfLytely - Reformulation
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03362216
Drug: Diclofenac Sodium Liniment
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
Trial: NCT01031108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Trial: NCT01031108
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Trial: NCT05296213
Drug: experimental tricalcium silicate
RxNorm normalized name: dicalcium silicate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Trial: NCT00225797
Drug: Oxymorphone Extended Release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01693562
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Trial: NCT03643276
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Trial: NCT03643276
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03299621
Drug: Muscle Relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
Trial: NCT03932292
Drug: Ectoin Mouth Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
Trial: NCT03932292
Drug: Supersaturated solution of calcium and phosphate ions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to medical prescription of the instruction for use under consideration (4 times a day).
Trial: NCT00395746
Drug: sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU agent
Trial: NCT00735852
Drug: Decapeptyl SR 11.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mgs, Intra muscular (IM) every 3 months for 2 years
Trial: NCT00441298
Drug: Placebo (Universal HEC placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Trial: NCT02429089
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients.
Trial: NCT00765830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qd
Trial: NCT01320033
Drug: Doxycycline 100 mg
RxNorm normalized name: doxycycline 100 MG
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
Trial: NCT01320033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Trial: NCT00446979
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
Trial: NCT00446979
Drug: UC 781
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
Trial: NCT03802201
Drug: PTG-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT02062099
Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04238793
Drug: KLS-2031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLS-2031 administered by transforaminal epidural injection
Trial: NCT02825641
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Trial: NCT00914095
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets of placebo 3 times a day
Trial: NCT01602640
Drug: Fentanyl and Midazolam infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional dose
Trial: NCT03898024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Trial: NCT03110549
Drug: TMB-607
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03110549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02705547
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily oral administration of Rosuvastatin (10 mg) for 3 months
Trial: NCT00369564
Drug: glutamic acid
RxNorm normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally 3 times daily
Trial: NCT02850744
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
Trial: NCT02532998
Drug: AZD9977 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977 oral suspension, single dose
Trial: NCT02532998
Drug: AZD9977 placebo oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, single dose
Trial: NCT02532998
Drug: Eplerenone, tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
Trial: NCT00004885
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004885
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01400698
Drug: Saizen® A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
Trial: NCT01400698
Drug: Saizen® B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
Trial: NCT00004885
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04265027
Drug: 50 mg BIA 9 1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard Capsule; Oral
Trial: NCT04265027
Drug: 25 mg BIA9 1067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard Capsule; Oral
Trial: NCT03172234
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery